DD269784A5 - Verfahren zur herstellung von oralen darreichungsformen mit verzoegerter abgabe - Google Patents

Verfahren zur herstellung von oralen darreichungsformen mit verzoegerter abgabe Download PDF

Info

Publication number
DD269784A5
DD269784A5 DD88315309A DD31530988A DD269784A5 DD 269784 A5 DD269784 A5 DD 269784A5 DD 88315309 A DD88315309 A DD 88315309A DD 31530988 A DD31530988 A DD 31530988A DD 269784 A5 DD269784 A5 DD 269784A5
Authority
DD
German Democratic Republic
Prior art keywords
carbamazepine
protective colloid
vinylpyrrolidone
dosage forms
added
Prior art date
Application number
DD88315309A
Other languages
German (de)
English (en)
Inventor
Satish Ch Khanna
Original Assignee
���@����������@��k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ���@����������@��k�� filed Critical ���@����������@��k��
Publication of DD269784A5 publication Critical patent/DD269784A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DD88315309A 1987-05-04 1988-05-02 Verfahren zur herstellung von oralen darreichungsformen mit verzoegerter abgabe DD269784A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH168287 1987-05-04

Publications (1)

Publication Number Publication Date
DD269784A5 true DD269784A5 (de) 1989-07-12

Family

ID=4216129

Family Applications (1)

Application Number Title Priority Date Filing Date
DD88315309A DD269784A5 (de) 1987-05-04 1988-05-02 Verfahren zur herstellung von oralen darreichungsformen mit verzoegerter abgabe

Country Status (21)

Country Link
US (1) US5122543A (da)
EP (1) EP0289977B1 (da)
JP (1) JPH01131117A (da)
KR (1) KR960006059B1 (da)
AT (1) ATE94390T1 (da)
AU (1) AU619178B2 (da)
CA (1) CA1328219C (da)
DD (1) DD269784A5 (da)
DE (1) DE3884044D1 (da)
DK (1) DK169608B1 (da)
ES (1) ES2043716T3 (da)
FI (1) FI882044A7 (da)
HU (1) HU199074B (da)
IE (1) IE63081B1 (da)
IL (1) IL86211A (da)
MX (1) MX11339A (da)
NO (1) NO881933L (da)
NZ (1) NZ224476A (da)
PH (1) PH24895A (da)
PT (1) PT87381B (da)
ZA (1) ZA883135B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
DE4422881A1 (de) * 1993-10-25 1995-04-27 Bayer Ag Kolloidal dispergierbare Wirkstoff-Formulierungen
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
IL136807A0 (en) * 1997-12-19 2001-06-14 Taro Pharmaceuticals Usa Inc Topical carbamazepine formulation and methods of use
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
NZ526608A (en) * 2000-12-22 2006-06-30 Baxter Int Method for preparing submicron particle suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
IN190699B (da) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9394327B1 (en) * 2013-03-15 2016-07-19 The Trustees Of California State University Nucleoside crystals, crystal nucleation and growth control with antifreeze proteins
JP2017537881A (ja) * 2014-11-18 2017-12-21 ピクサーバイオ コーポレーション 急性、術後、または慢性疼痛を治療する組成物およびその使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4213963A (en) * 1978-12-14 1980-07-22 Janssen Pharmaceutica N.V. Fluspirilene-containing compositions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
JPS59147374A (ja) * 1983-02-10 1984-08-23 Fuji Xerox Co Ltd 電子写真複写機のブラシクリ−ニング方法
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
ATE78404T1 (de) * 1985-05-02 1992-08-15 Ciba Geigy Ag Hydrogele mit erhoehter beladungskapazitaet bezueglich einer in einem organischen loesungsmittel loeslichen wirksubstanz, deren herstellung sowie deren verwendung.
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
JPH0641286B2 (ja) * 1987-05-14 1994-06-01 信行 西井 自動包装装置
US4964606A (en) * 1989-10-26 1990-10-23 Ncr Corporation Overhead mount for a CRT

Also Published As

Publication number Publication date
IE881328L (en) 1988-11-04
DK238888D0 (da) 1988-05-03
JPH01131117A (ja) 1989-05-24
NZ224476A (en) 1990-09-26
NO881933D0 (no) 1988-05-03
ZA883135B (en) 1988-11-07
AU619178B2 (en) 1992-01-23
ES2043716T3 (es) 1994-01-01
CA1328219C (en) 1994-04-05
DE3884044D1 (de) 1993-10-21
PT87381A (pt) 1989-05-31
ATE94390T1 (de) 1993-10-15
HUT46847A (en) 1988-12-28
DK169608B1 (da) 1994-12-27
HU199074B (en) 1990-01-29
FI882044L (fi) 1988-11-05
IL86211A0 (en) 1988-11-15
AU1555888A (en) 1988-11-10
EP0289977B1 (de) 1993-09-15
MX11339A (es) 1993-12-01
FI882044A7 (fi) 1988-11-05
KR960006059B1 (ko) 1996-05-08
EP0289977A1 (de) 1988-11-09
DK238888A (da) 1988-11-05
PH24895A (en) 1990-12-26
IE63081B1 (en) 1995-03-22
IL86211A (en) 1992-03-29
KR880013550A (ko) 1988-12-21
NO881933L (no) 1988-11-07
FI882044A0 (fi) 1988-05-02
PT87381B (pt) 1992-08-31
US5122543A (en) 1992-06-16

Similar Documents

Publication Publication Date Title
EP0289977B1 (de) Orale Darreichungsformen mit verzögerter Abgabe
DE3884461T2 (de) Antibiotikum-Polymer Zusammensetzung.
DE2845326C2 (de) Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
AT410896B (de) Teilchen enthaltend biologisch aktives peptid
DE69627835T2 (de) Feste pharmazeutische zusammensetzung aus nanopartikeln
DE69832108T2 (de) Fenofibrathaltige Arzneizusammensetzung mit erhöhter Bioverfügbarkeit und Verfahren zu deren Herstellung
DE69732312T2 (de) Schnellzerfallendes Granulate von einem synthetischen Süssstoff enthaltend Kieselsäure und/oder Siliciumdioxid
DE69732049T2 (de) Pharmazeutische zubereitungen, enthaltend salze von hyaluronsäure und lokalanästhetika
DE69634733T2 (de) Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie
DE3124014A1 (de) Aluminiumibuprofensuspensionen
DE112013004278T5 (de) Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
DE69213836T2 (de) Megestrolazetat-Formulierung
DE69511539T2 (de) Eine cyclosporin enthaltende zubereitung und ein verfahren für ihre herstellung
DE60309839T2 (de) Feste lösung einer schwerwasserlöslichen substanz zur oralen verabreichung
DE19614823A1 (de) Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge
DE60121574T2 (de) Festes dispersionssystem von pranlukast mit verbesserter auflösung und methode zu dessen herstellung
DE69128760T2 (de) Antidiarrhoeika
WO2019154896A1 (de) Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche
DE69819900T2 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
DE69130832T2 (de) Injizierbare amphotericin b enthaltende dispersion
DE3882042T2 (de) Antiallergische augentropfen.
DE69123248T2 (de) Verfahren zur herstellung einer wässrigen suspension
DE69630639T2 (de) Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
EP0445158A1 (de) Zubereitungen des oxipurinols und/oder seiner alkali- oder erdalkalisalze.
DE2950476A1 (de) Fluspirilene enthaltende waessrige arzneipraeparate zur intramuskulaeren gabe

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee